GlassScriptPhysician profile
Yvemith Aluc
NPI 1568968071
$6,649.72
in general payments reported to CMS, 2019-2025
26 companies · $2,491 in 2025
The $2,491 reported for 2025 was more than what 98% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $608 · 2023: $1,482 · 2024: $2,068 · 2025: $2,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,015 · Education: $26.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,015.27 |
| Education | $26.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,460.37 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $1,113.50 | 2022-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $972.34 | 2022-2025 | |
| Corium, LLC | $481.62 | 2022-2025 | Azstarys |
| Catalyst Pharmaceuticals, INC. | $316.99 | 2023-2025 | Fycompa |
| Collegium Pharmaceutical, INC. | $199.19 | 2025 | Jornay Pm |
| Aucta Pharmaceuticals, INC. | $151.88 | 2025 | Motpoly Xr |
| Ironshore Pharmaceuticals INC. | $147.44 | 2022-2024 | Jornay Pm |
| Sumitomo Pharma America, INC. | $110.08 | 2023 | Aptiom |
| Eisai INC. | $102.52 | 2022-2023 | |
| Aquestive Therapeutics, INC. | $88.31 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $63.77 | 2025 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $53.69 | 2022-2023 | Elaprase |
| Sk Life Science, INC. | $52.48 | 2023-2024 | |
| Otter Pharmaceuticals, LLC | $49.43 | 2025 | Sympazan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $42.19 | 2024 | Zonisade |
| Mirum Pharmaceuticals, INC. | $41.56 | 2024-2025 | Cholbam, Cholbam |
| Immedica Pharma US, INC. | $33.81 | 2024 | |
| Alexion Pharmaceuticals, INC. | $27.90 | 2025 | Koselugo |
| Livanova USA, INC. | $27.74 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $25.54 | 2023 | Qelbree |
| Tris Pharma INC | $24.96 | 2025 | Dyanavel Xr |
| Cranial Technologies, INC | $18.51 | 2024 | Doc Band |
| Noven Therapeutics, LLC | $17.03 | 2024 | Xelstrym |
| Biomarin Pharmaceutical INC. | $13.86 | 2024 | Brineura |
| Metacel Pharmaceuticals LLC | $13.01 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvemith Aluc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.